Voriconazole

CHEMBL638 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

349.3 g/mol

LogP

1.5

Phase

4

This broad-spectrum antifungal medication is used to treat serious and potentially life-threatening fungal infections, particularly invasive aspergillosis and certain other mold and yeast infections in immunocompromised patients such as those undergoing bone marrow transplants. It is available in both oral and intravenous forms and works by blocking a key enzyme in the fungal cell membrane synthesis pathway. It interacts with many medications and can cause visual disturbances, liver toxicity, and sun sensitivity.

Moleküler Ağırlık

349,3100 g/mol

LogP

1,50

TPSA

76,70 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Hematology Pain Management Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Insomnia Infectious Disease Melanoma Oncology Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain HIV/AIDS Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F

InChI

InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

Molecular Formula

C16H14F3N5O

HBD / HBA

1 / 8

Döndürülebilir Bağlar

5

Ağır Atomlar

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This broad-spectrum antifungal medication is used to treat serious and potentially life-threatening fungal infections, particularly invasive aspergillosis and certain other mold and yeast infections in immunocompromised patients such as those undergoing bone marrow transplants. It is available in both oral and intravenous forms and works by blocking a key enzyme in the fungal cell membrane synthesis pathway. It interacts with many medications and can cause visual disturbances, liver toxicity, and sun sensitivity.

Yes, Voriconazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL638. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71616. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Voriconazole PillFYI'da

Yapı

Hızlı Veriler

Formül: C16H14F3N5O
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.